NDA 207223 · Biocodex SA
Diacomit
Stiripentol · Oral
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Apr 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Aug 20, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
14
4 Phase 3, 2 recruiting
FAERS reports
2,283
1,959 serious, 121 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 27, 2026.
DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more. There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome. DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more . There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome. ( 1 )
Mechanism: The mechanism by which DIACOMIT exerts its anticonvulsant effect in humans is unknown. Possible mechanisms of action include direct effects mediated through the gamma-aminobutyric acid (GABA) A receptor and indirect effects involving inhibition of cytochrome P450 activity with resulting increase in blood levels of clobazam and its active metabolite.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 14, 2022 Supplement 3 · Efficacy OrphanLabelLetter
- Aug 20, 2018 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelMedication GuideLetter
2 products under this application
- DIACOMIT · STIRIPENTOL 500MG/PACKET · FOR SUSPENSION, ORAL · Prescription
- DIACOMIT · STIRIPENTOL 250MG/PACKET · FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Stiripentol" as an intervention, any sponsor and status, largest first.
- Ketogenic Diet in Infants With Epilepsy (KIWE)Pivotal-lookingStatus unknown
University College, LondonAcademic, hospital or other
NCT02205931 · 160 participants (planned) · Start Jan 2015 · Primary completion Jun 2018
Drug: Antiepileptic drug therapy · For: Epilepsy
Sites: Birmingham, United Kingdom; Bristol, United Kingdom; Cambridge, United Kingdom · 11 sites in all
- A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.Pivotal-lookingActive, not recruiting
Zogenix, Inc.Industry
NCT05064878 · 87 participants · Start Mar 8, 2022 · Primary completion Nov 8, 2027
Drug: Fenfluramine; Placebo · For: CDKL5 Deficiency Disorder; Generalized Tonic Clonic Seizure; Epileptic Spasm and 1 more
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 46 sites in all
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.Industry
NCT02926898 · 87 participants · Start Jan 27, 2017 · Primary completion Jun 5, 2018
Drug: ZX008 (Fenfluramine Hydrochloride); Matching Placebo · For: Dravet Syndrome
Sites: San Francisco, California; Aurora, Colorado; Chicago, Illinois · 28 sites in all
BiocodexIndustry
NCT05419180 · 52 participants · Start Oct 13, 2022 · Primary completion Jun 13, 2024
Drug: Stiripentol · For: Pharmacoresistant Focal Epilepsies
Sites: Paris, France
- Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3Pivotal-lookingRecruiting
BiocodexIndustry
NCT06465472 · 42 participants (planned) · Start Sep 23, 2026 · Primary completion Aug 2030
Drug: Stiripentol Oral Capsule; Placebo Oral Capsule and 2 more · For: Primary Hyperoxaluria Type 1; Primary Hyperoxaluria Type 2; Primary Hyperoxaluria Type 3
Sites: Paris, France
BiocodexIndustry
NCT05735951 · 39 participants · Start Jul 24, 2023 · Primary completion Nov 30, 2024
Drug: STIRIPENTOL oral administration · For: Chronic Renal Insufficiency
Sites: Sofia, Bulgaria
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT02607891 · 35 participants · Start Nov 9, 2016 · Primary completion Sep 11, 2018
Drug: GWP42003-P; Placebo · For: Epilepsy
Sites: Zwolle, Netherlands; Barcelona, Spain; Madrid, Spain · 5 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT02607904 · 30 participants · Start Dec 15, 2016 · Primary completion May 27, 2019
Drug: GWP42003-P · For: Epilepsy
Sites: Zwolle, Netherlands; Barcelona, Spain; Madrid, Spain · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure928
- off label use443
- product use in unapproved indication351
- drug ineffective306
- decreased appetite265
- somnolence246
- product preparation issue201
- product dose omission issue186
- fatigue138
- pyrexia113
- weight decreased111
- hospitalisation107
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 12 |
| 2012 | 5 |
| 2013 | 7 |
| 2014 | 5 |
| 2015 | 21 |
| 2016 | 14 |
| 2017 | 42 |
| 2018 | 50 |
| 2019 | 239 |
| 2020 | 247 |
| 2021 | 284 |
| 2022 | 276 |
| 2023 | 186 |
| 2024 | 234 |
| 2025 | 303 |
| 2026 | 337 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Diacomit (Stiripentol)
2024 spending
$1.7M
Beneficiaries
32
296 claims
Per beneficiary
$54,459
$41.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $468,575 |
| 2022 | $854,407 |
| 2023 | $1,207,655 |
| 2024 | $1,742,694 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
Guerrini R, Chiron C, Vandame D, et al. · Epilepsia Open 2024 · Systematic Review, Comparative Study
- Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial.
Sullivan J, Lagae L, Cross JH, et al. · Epilepsia 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, et al. · Epileptic Disord 2022 · Systematic Review
- Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Nabbout R, Mistry A, Zuberi S, et al. · JAMA Neurol 2020 · Multicenter Study, Randomized Controlled Trial
- Tough to treat: What we know about managing PCDH19-related epilepsy - Systematic review.
Tobiasz A, Hager M, Dwbowska J, et al. · Seizure 2025 · Systematic Review
- Stiripentol for focal refractory epilepsy.
Brigo F, Storti M, Igwe SC · Cochrane Database Syst Rev 2015 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Biocodex SA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.